OncoMatch/Clinical Trials/NCT05093907
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer
Is NCT05093907 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including BEY1107 and Capecitabine for metastatic colorectal cancer.
Treatment: BEY1107 · Capecitabine — This is a Phase 1/2 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with capecitabine in patients with metastatic colorectal cancer refractory or intolerant to standard of care (SoC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy (fluoropyrimidine, oxaliplatin, irinotecan) — second-line or beyond
Patients who experienced treatment failure of colorectal cancer with the second-line or beyond standard chemotherapy (including fluoropyrimidine, oxaliplatin and irinotecan)
Cannot have received: radiation therapy
Patients who received radiation therapy, chemotherapy or biological agent including hormone therapy recently
Cannot have received: chemotherapy
Patients who received radiation therapy, chemotherapy or biological agent including hormone therapy recently
Cannot have received: biological agent
Patients who received radiation therapy, chemotherapy or biological agent including hormone therapy recently
Cannot have received: hormone therapy
Patients who received radiation therapy, chemotherapy or biological agent including hormone therapy recently
Cannot have received: other investigational product
Subjects who had been administered other IP within 4 weeks prior to screening
Lab requirements
Blood counts
laboratory findings of inadequate bone marrow function excluded
Kidney function
laboratory findings of inadequate kidney function excluded
Liver function
laboratory findings of inadequate liver function excluded
Subjects who has labortory findings of inadequate bone marrow, kidney and liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify